

8 December 2025

ASX Announcement

Amy Demediuk appointed Company Secretary and General Counsel

PolyNovo Limited (**PolyNovo** or **Company**) announces the appointment of Ms. Amy Demediuk as Company Secretary and General Counsel effective 16 February 2026.

Ms. Demediuk has extensive experience managing legal, risk, and compliance functions of ASX-listed tech and healthcare companies. She brings significant experience in mergers and acquisitions, capital markets, corporate law, licensing, and intellectual property.

Most recently, Ms. Demediuk served as General Counsel (Global R&D and Strategy) for CSL (ASX: CSL). She joined CSL in 2009 and held various Counsel roles supporting CSL's Australian operations, including CSL's corporate, R&D, plasma and influenza manufacturing businesses. She also led CSL Behring's legal team supporting all manufacturing and commercial activities across the Asia Pacific region and led the legal team supporting global R&D and corporate development initiatives, including most recently, a 2+ year term in the USA.

Ms. Demediuk began her career at Arnold Bloch Leibler where she worked for 3 years. She holds a Bachelor of Laws (Honors) and Master of Laws (Intellectual Property) from the University of Melbourne. She is admitted as a Barrister and Solicitor of the Supreme Court of Australia and recently passed the New York bar exam.

CEO, Bruce Peatey said: *"The Management Team is thrilled to welcome Amy to PolyNovo. Her depth of expertise and proven leadership will be instrumental as we build on our strong momentum and pursue the next phase of growth. I am confident her contribution will create significant value for our business and stakeholders."*

Chair, Leon Hoare said: *"We are delighted to have Amy join PolyNovo. She brings extensive, highly relevant experience and a readiness to immediately make an impact as a core member of the leadership team. We look forward to Amy enhancing PolyNovo's capability across both her roles."*

This announcement has been authorised by PolyNovo Company Secretary, Jan-Marcel Gielen.

About PolyNovo®

PolyNovo is a disruptive medical technology company, headquartered in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 84,000+ patients across 46 countries, the company is investing for growth via new products, indications, and markets. For more information see polynovo.com

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

About NovoSorb MTX®

NovoSorb MTX leverages the technology platform underpinning the clinical success of NovoSorb BTM, but **without a sealing membrane**, and is designed to support natural wound healing, especially for wounds that are highly exudative or those with an uneven wound bed. The product was developed to satisfy clinician demand for a product for use in indications where the sealing membrane is not required.

About Beta Cell

PolyNovo is supplying NovoSorb BTM to Beta Cell Technologies Pty Ltd for clinical trial purposes following positive results of the First in Man proof of concept study. The study involved transplanting human pancreatic islets into an alternative neovascularized site within the skin for 3 trial participants using NovoSorb BTM to create a cell supporting vascular bed.